Subtitles section Play video Print subtitles >> Ladies and gentlemen welcome to the 2013 Royal Society GlaxoSmithKline Prize Lecture. I'm Jean Thomas, I'm the Biological Secretary and I have the housekeeping duties of asking you to turn off your mobile phones, please, because the lecture is being recorded and webcast. And also, to tell you in the that actually, I hope, unlikely event that there's a fire, you don't go out through the usual doors but you, because of the snow and whatever, you go out through these doors instead. So, 2013 is the Royal Society Year of Science and Industry. This is the year when the society will showcase excellence in UK industrial science and strengthen links between the society industry and academia. The Royal Society recognizes that world class research and development in the UK industry is essential for transforming innovative ideas into commercially successful products into its economic growth and securing the science space. And it will be proactive in anticipating, understanding, and responding to the needs of industry's scientists. Symposia and meetings with high industry interests have been added already to the society's calender which already includes longstanding initiatives in scientific excellence, such as the Royal Society Industry Fellowship and the Brian Mercer Awards for Innovation and Feasibility. So, the year of science, science and industry will bring a renewed focus on engaging with the industrial sector to develop cogent arguments that high level investment in the UK science space is essential for international competitiveness. Something we would all, I'm sure, sign up to. Now, to the prize and the lecturer, the Royal Society GlaxoSmithKline Prize and Lecture is awarded biannually for original contributions to medical and veterinary sciences published within 10 years of the date of the award. The prize consists of a very nice gold medal, an even nicer check for 2,500 pounds, and the recipient is called upon to deliver an evening lecture at the Royal Society which is why we're all here this evening. And this is really a, a capacity audience, and the reason we're a few minutes late starting is that there is an overflow room, and I don't remember that in the last, certainly, in the last four years of chairing these evening lectures. So, Adrian has really put in a big crowd tonight. So, no pressure there, Adrian, at all. It was, the award was initially established following a donation from the Wellcome Foundation. First award was made in 1980 the centenary of the work and foundation and since 2002, it is being supported by GlaxoSmithKline Limited. So, this year's recipient of the prize is Adrian Bird an old friend and colleague, I'm delighted that he's received this award. Adrian has held the Buchanan Chair of Genetics at the University of Edinburgh since 1990. And he's a member of the Wellcome Trust Center for Cell Biology in Edinburgh. His research focuses on the basic biology and biomedical significance of DNA methylation and other epigenetic processes. His laboratory identified CpG islands as gene markers in the vertebrate genome. And he discovered proteins that read the DNA methylation signal to influence chromatin structure. Mutations in one of these proteins, MECP2, and I'm sure we'll hear a lot more about this, this evening, causes the severe neurological disorder Rett Syndrome, which is the commonest genetic cause of mental retardation in females. Adrian was made a Fellow of the Royal Society back in 1989. He's received several awards, numerous awards for his work, including notably the Louis-Jeantet Prize for Medicine, the Charles-Leopold Mayer Prize of the French Academy, and the Gatineau Prize. This evening, it's the turn of GSK and the Royal Society to give him this special GS Royal Society, GSK prize. And has to give his lecture in order to earn that. His lecture is entitled, as you can see, Genetics, Epigenetics, and Disease. So, Adrian, over to you. >> Thank you very much, Jean. Thank you very much for this award. It's a great honor to, to be asked to give this lecture. And thank you very much for braving the elements to come and listen. I think, probably the title of Genetics, Epigenetics, and Disease is broad enough that it sounds like it's going to change all our lives in this next 45 minutes. But in fact, I'm going to focus on a relatively small part of it ultimately. But I'm going to start off reasonably broad. There's one deliberate mistake on the, the first slide. I hope it's the last one. It's the year. So let's go back in time to the draft sequence of the human genome because this was a, heralded as a, a time when biology really became a, a hard science. If you like, it was seen as the, the beginning of the end. We now knew the entire code for all, we knew the sequence of all the genes required to make a human being. But it's pretty clear that it was actually the end of the beginning. And the somewhat apocalyptic predictions that now one simply had to automate, the discovery of all the medical innovations that would result from the genome sequence was premature. In fact, it's likely in my opinion that there's still another century of biology to be done and this will be an exciting century of discovery converting the promise of the genome into the reality of biomedical applications. And that, one of the issues I think that, that, that we would really love to be able to solve, a big, a big question if you like, is where DNA, despite being the thread of life, you can put it in a tube and gaze, gaze at it for as long as you want and it remains utterly dead. So the question is really what does it take to make it alive? When Craig Venter synthesized a bacterial genome an important synthetic biology milestone, it had to be put into a living cell before it became alive. How can one bypass that? As the chemists say, you only really understand something if you can make it. We can't actually make life but it would be good to know some of the rules required to do that. So, some key unanswered questions about the genome that, that remain and this is only a selection. First of all a basic fact, genes make proteins, here is the chromosome, here is the sequence of the genes, there is the RNA. It encodes the sequence of the amino acids that lead to the protein that folds up to then do all the lifelike things that are required. But how are only the right genes expressed in a cell type? This has been a question, a long standing question. Do we know the answer to it? Why globin is expressed in blood cells and keratin is expressed in skin cells, etcetera. We, we approximate knowledge about it, but actually, there's an enormous amount to find out. Most of the genome is actually inaccessible. This is this gray, it's rather difficult to look at this picture I think because the DNA is gray and looks although it should be in the background but this is a nucleusome, the repeating unit of the, of the chromosome, if you like. The fundamental repeating unit. And the DNA clings to the outside of it. And proteins that want to make genes active, can't actually get at the DNA properly. So, how does the gene activation machinery gain and how does it keep access? Again, we have some beginning answers to this, but we don't, by any means, have a full picture. Protein-coding DNA sequences are only 1% of our genome. So, if you look at a piece of the human genome, you see these vertical stripes correspond to the bits of this gene that are separated from each other. In fact genes are fragmented and they are a tiny minority of all the DNA. What is the rest of it for? There is an enormous, there's a vast majority that is, that we can't explain. This isn't the case with all organisms. This, for example, is yeast, and you can see now the genes are packed together. It's difficult, it used to be said casually that the rest of this DNA was just junk. But now, it's sort of almost politically incorrect to call it junk. It's particularly after the encode project which found lots of potential regulatory sequences throughout here. So, this other DNA is doing stuff. And perhaps, it's doing stuff that makes for example, humans and other mammals far more complex than yeast. So finally, there are questions almost sociological questions. Does the environment have any impact on gene expression? And this is a, a question I'll allude to in a moment. But it's not one that is the main subject to this, this talk. So, I put in the title Epigenetics because I'm quite mine, our work is quite often described as epigenetics. It literally means above or in addition to genetics. But the definition has been controversial and I'm just going to skim somewhat lightheartedly over some of this because it's, it's at meetings to do with Epigenetics. One can see various opinions expressed with varying degree, this one I believe was in Barcelona with great vehemence. So, let me just try to sort of consolidate this. The original epigenetics definition comes from Conrad Waddington, who was actually my predecessor as Buchanan Chair, Chair, Chair of Genetics in Edinburgh. And what he meant was in contrast to pre-formationism, but the development proceeded by the gradual unfolding of the information in the genes, to produce the whole organism. So, for him, how information of the genes is read during embryo, during embryonic development to give the whole organism was the essence of what epigenetics was about. We would now call this developmental biology. How the genotype gives rise to the phenotype. But it's acquired, or a sort of, a special status in epigenetics, really, because of this iconic picture, the epigenetic landscape. I'm not going to dwell on this either. Because quite honestly, having had it explained to me several times, I'm never totally sure, exactly how this helps. It's a picture of a bull rolling down a hill. The number of options for the bull get progressively less. But I don't feel that this encapsulates anything very useful. This, however, is a fundamentally important question that remains on our agenda. Second definition of epigenetics which is rather different has actually different origins epistemological origins. How characteristics are inherited across cells or organism generations without changes in the DNA, its sequence, itself. An example of this is this cat, the so-called tortoise shell cat, or calico cat, in, in, in the US, which has these patches of fur. It has two x chromosomes. One of them has a gene that gives black fur, the other one has a gene that gives orange fur, and cells early in development, inactivate one or the other of those chromosomes for, for reasons we don't, which I will, I will come back to actually, a little bit later. And you get a patch of skin because the cell that originally inactivated the orange fur gene gave rise when it divided to cells that did exactly the same thing. So, that was inherited. All the gene or the, the DNA is still there in these cells, in, in the orange ones, and the black ones, but there is difference that is inherited and that's epigenetic according to this definition. So, heritable traits of this kind might be influenced by the environment. And this is sort of revitalized that an ancient argument about nature versus nurture, where nature is genetics, the idea that we're, our genes are, are in control and nurture is the opposite, the idea that our environment determines who we are. Of course, it's a mixture of both but epigenetics has given a, a, a new lease of life to the nurture argument. And so, one can see articles such as this and there are many examples I could have chosen why your DNA isn't your destiny, the new science of epigenetics reveals how choices you make can change your genes and those of your kids. Now, I'm not an expert on some of the epidemiology behind this, but the, the molecular biology, in my opinion, is far less convincing than it is for other aspects of epigenetics. It is, however, an extremely interesting idea, that the environment can give rise to changes that get passed on, but it is systematically overstated in a lot of places one finds it described. So, one has to be circumspect about the, this kind of argument in my opinion. There are couple of excellent examples in plants, in worms where immune, immunity is involved, but some of the more sociological aspects, in my opinion, require further evidence. So, I'm sticking with this as my example of heritable epigenetics. It's closer to the molecular biology we actually understand. So, Epigenetics 3, biological significance of the epigenome. Another definition, it's risen pragmatically. What is the epigenome? Well, here is a genome of a, of a cell. It's, it's the chromosomes that were obviously designed for an experiment because there are fluorescent pinpoints here. Ignore those, that's a human chromosome compliment. If you explode those chromosomes, you see beads on a string and this is that repeating unit I referred to earlier, the nucleosome with the DNA going round the outside. It looks like beads on a string. So, the epigeno, epigenome refers to markings of those beads, of that string of beads in such a way that the region, it is regionally, regionally adapted to its function. So, for example, there can be a region where gene is stably ON, and there is a whole plethora of marks that appear that reinforce that decision. And similarly stably here, a gene OFF, such as the black-coat gene in our orange patch of fur. And again, you get adaptation, and this is the epigenome, and the study of what the epigenome means, is another definition of epigenetics. So, you have DNA methylation here where these methyl groups are added to the DNA. You can't do much to DNA without changing its propterties, its important properties. Almost, the only thing it seems you can do is put these methyl groups on and even that is bad in a way. I don't have time to go into, it causes an increase in the frequency of mutations. But the, by far, the most elaborate way of marking the chromosomes, is via these beads which, invisibly on any of the structures I've shown you before previously, have tails. And these tails are basically ticketing entities that you can add chemical information to. That the cells can write information in the form of chemical alterations. And so, you add this and, that says, stably ON or stably OFF. Again, we have the broad outlines. We can correlate quite a lot of these with activity and silence. But if you were to ask exactly what each of these modifications does, we have, still have a lot to learn. So, if you like, it's the, epigenetics is the structural adaptation of chromosomal regions so as to register signal, or perpetual, perpetuate altered activity states. And importantly, proteins that read these marks, write the marks, or erase the marks, remove the marks are implicated in human disease and quite a lot of excitement in pharma including GSK is devoted to finding out what these drugs might be good for in terms of human disease. So, epigenetics then embraces key unsolved problems in Biology, how, how the genotype give rise to phenotype, that's the Waddington one, how traits are inherited across cell or organism generations without changes in the DNA sequence and how structural adaptation of the genome facilitates gene activity programs. As far as I'm concerned, this is not a word one needs to dwell on with sort of almost a theological interest about what it means. Everything it possibly means is interesting. So, let's get on with studying it. And I, I like to think of it as how the genome is organized and managed to make DNA if you like, come alive. So CG is one such signal it's one of those marks and you'll notice CG is not actually a, a mark, it's actually a sequence, it's a 2 based pair sequence. Dna sequences that recognize proteins are usually longer than that because they're rarer. If you have a sequence of one base, every few bases you come across it, and it doesn't have much information. Two bases is not much better, but nevertheless, as you will see, CG is used as a genetic signal and also as an epigenetic signal. So, here's a piece of DNA, flattened out so it's no longer helical. Those two strands are anti-parallel and CG is paired with itself. So, CG pairs with CG. This TA is paired with itself, but it's nearly so interesting. And one of the things we'll talk about that can happen to CG is that the C can get, gets methylated. And that, since there are two of them, that can be a symmetrical event. And it looks like this, they sit in the major grooves. I've already shown you a different picture, though with less vulgar coloring that shows the two methyl groups sitting in the major groove and they influence interactions between proteins and DNA. So, what are the features that adapt CG for a genome signalling function? The first is that, as I've mentioned, you can get it in, in three different chemical forms, actually there are more than three, there are another two but that, it's not yet clear whether these are biologically important or just by-products, at least it's not clear to me. You have CG unadorned, you have CG methylated, and you have CG where the methyl group has had an oxygen added to it, and it becomes hydroxy methylated. So, it exists in different forms. Specific proteins are attracted or repelled by different modified forms and we're going to talk more about that. Highly variable in frequency, so then, the frequency of CG despite the fact that it's just a two base per sequence is dramatically different going along the genome. In the bulk of the genome, 99%, it's quite far apart. These lollipops represent CGs. The lollipops that are solid represent methylated ones and the open ones represent unmethylated ones. So, 99% of the genome has not many CGs and most of them are methylated. But then, there are these clusters where the density is about 10 times higher and these are the so-called CG islands. They are interesting because they sit right on top of the control regions for genes. So, here's a gene, it's red in this direction and then these blue bits are spliced together to make the messenger RNA. And sitting right on top of the promoter is this CG island, and this amounts to about 1% of the genome. There's another one there. And here's a biological consequence of the methylation. If you look at this CG island, it can, under certain circumstances, this happens on the inactive x, this happens at imprinted genes. It happens at germline genes in the soma, it happens in cancer, abberantly. It gets methylated. And when that happens, you shut down transcription of the gene. And because methylation is something I haven't gone into, is relatively stable, it can be transmitted from one generation to another, if you like, copied. When cells divide one cell generation to another, it's this is quite a stable[UNKNOWN]. So, one of the things DNA methylation does, is it shuts down the expression of genes. So, we're gonna talk about specific proteins that are attracted or repelled by modified forms of, of CG. And I'm gonna start just with a protein that recognizes unmodified CG so it cant recognize this or this. So, Cfp1, sorry about the acronyms, it's a, it's a protein that recognized, it was discovered, in fact, by David Skalnik it binds to non-methylated CG. I don't know why I've drawn the DNA at this jaunty angle, but it, it just meant to show that it's interacting with it. And it also interacts with a complex of proteins. An enormous complex, well, relatively big complex, called set 1. And this complex does something to the nucleusome. We've seen this before, this is the bead on the string, the DNA going round the outside. Haven't, in, in, when you look, determine the structure of something like this, you don't find the tails, the things that you write on. And so, I've drawn them freehand, nobody actually knows where they are because they're so floppy, they don't come up in the x-ray structure. But, amino acid lysine number 4 gets methylated and this is done by this complex. So, we have a protein that binds to non-methylated CG that recruits a complex that methylates this. Now, why is that interesting? This is a mark of active genes, so if we look where CG island are, CpG island as they're more often called, in fact, here are the CpG islands, I'm not going to tell you how we know they're there. But you'll notice these, this gene is going this way, there's a CpG island at the start of it. This gene is going this way, actually bidirectionally, there's one going this way, one going this way, there's the CpG island. So, they're all the CpG islands, there's the RNA polymerase, the protein, the machine that makes that starts to be converted, copied into to messenger RNA. And it's just at the beginning of them because this is the, a particular form of RNA polymerase that is only at the beginning of genes. And here is this mark, H3K4me3, which means this purple blob on this tail, which is put on here. So, we have the non-methylated CG cluster here and we have the mark, and this mark is involved in gene expression. So could it be that the, the proteins attracted by the CG brings in this and that's what causes this mark? If you look as, as we did where the protein is, it coincides with the CpG islands. So, it's in the right place. If you take it away, the k4 trimethylation, this, these peaks here go down and that's consistent with the idea that this is reading the CpG island signal but the key experiment is really the Pete Skene and John Thomson did is to insert a piece of CpG-rich, CG-rich junk into the genome, real junk in fact, it's not actually quite junk, it's the jelly fish gene that's been optimized for expression in humans lacking any control sequences, just inserted into the genome, so you make a CG island like sequence with a cluster of CGs. Now, are you creating a new H3K4 trimethylation peak? So, here's a, here's a map of all the CGs. The vertical lines show where they are and this is what we've inserted. And you can see the density of CGs has gone up. And now, you can plot that density. Now, where's Cfp1, the protein that binds CG. There it is. We've now got a new peak of it. And what about H3K4 trimethylation? It's there, too. And you notice, where there's most CG, there's most, more, most of that modification. Is there, have we just made a gene? In other words, all the stuff that does geney things is there. No. Because there's no RNA polymerase there. So, this is just the DNA sequence, talking to the chromatin. And, and as one can do this with other sequences and verify that it's the case. So, a CG-rich piece of DNA creates a new region of H3K4 trimethylation, this active promoter mark, even when there is no active promoter there. So, the presence influences of the CGs influences the chromatin structure via this link between the DNA binding proteins and the set enzyme complex and other CG binding proteins also recruit, rcruit modifying enzymes. In fact, for a long time, we were used to the fact that CG islands existed, but we didn't really know what they were for. And, and actually, one almost forgot to ask, well, they're always there, what are they for? In fact, it now seems very likely that they are platforms to set up appropriate genome structures at gene promoters. Very important function. And there are other proteins that bind CG, that recruit other things to them, and this is a very, a rapidly growing area. So, suddenly, we find that the CG island is a, is a, is a, a structure of biological importance, and we're starting to disentangle how. So here is a CXXC protein which has its domain. Cxxc is the name of the protein domain that binds CG. It comes in wearing this ludicrous wig. And creates a sunny promoter gene, gene activity friendly region of the genome. If there was a methyl CG,it comes in and it is goes away. It can't bind. So now, I'm going to turn to for the rest of my talk proteins that bind to the methyl CG mark, the one with the purple blobs on. The purple blobs that were on the DNA, not the purple blobs that was on, was on the histone tail. So, what binds this form of CG? Well, a protein that we found a long time ago is MECP2, and this binds, specifically, and I'm going to show you some of the prehistory of this protein. First of all, a picture from the paper and you could either take from this how prescient he was, to be able in 1992, to find this protein that turns out to be so interesting. Or you can think, he's been working on that protein for 21 years and he's still not quite sure where it does. Let's you can shoot, take your pic at the end of, of the talk. So this shows how we first found it. We run the proteins that are in a nucleus on a gel. And then, we probe them with a piece of DNA that's labeled and methylated. And then, the same sequence of DNA with no methylation. And clearly, there's a protein that bind one that's methylated and at about 84 kilodalton and doesn't bind when it's not. And we now know a structure for this in, in an atomic detail. Here are the two methyl groups sitting in the major group. And this is the domain of this protein that interacts with them. So, we were happily studying this for blue, blue skies reasons to, to try to find out a protein that read DNA methylation and therefore a reader of DNA methylation, and find out what it did. When Huda Zoghbi showed that the gene that causes Rett Syndrome, an autism spectrum disorder, is almost exclusively, more than 90% MECP2. So, this is the gene that is mutated in Rett Syndrome. So, what is Rett Syndrome? This is a, a, a film just taken from YouTube, not somebody I have ever met but you can see the characteristic features of Rett Syndrome which involve this repeated hand clasping and a period of apparently normal development saw 6-18 months, and then regression, progressive encephalopathy, repetitive hand movements, breathing a, a, arrythmia, a, a profound problem. But nevertheless, a life expectancy of about 40 years on average. So, there is no effective treatment and 24-hour nursing is required. So, this was all caused not by a brain gene, that was what was being looked for by everybody. And those were in the days where you thought the gene would have something to do with the, the, the tissue that was affected, but a basic housekeeping protein that reads DNA methylation that's expressed in every cell type. So, why does this disorder only affect girls? Well, you probably guessed it's because it's on the x chromosome. Males are always more affected by mutations in genes on the x chromosome than females because they only have one x and females have another one which can compensate and males die. There is no male Rett Syndrome simply because males don't survive. So then you have a new mutation. Nearly always as it happens like many of these things, paternally derived. And then proceeds x chromosome inactivation. I remember so, in order that females have only the same number of functional x chromosomes as males, they shut one off. And this happens in random cells and I've shown you the example of the cat and I'll show you the cat again. X, this gene, this cell inactive[UNKNOWN], this progeny of this cell inactivates this x chromosome this one inactivates the other one and this then is inherited so this is the epigenetic inheritance phenomenon it's passed on. And the end result is, there's the wretched cat again but with his different things, I will show you a different example of that in a moment. But the, this, well, the point to be made here is that the brain and, in fact, the other tissues of a Rett patient consist of a mosaic of a salt and pepper mixture of cells that are functionally normal with respect to MECP2 and cells that are functionally without normal, I mean, without MECP2. So here, for example, if the phenomenon a new mutation arises, sometimes, that mutation is the only MECP2 in the cell, and the other time, it's invisible. And you just get the wildtype express. So, this is the mosaicism. Now, the equivalent of the cat picture in the brain, though, is rather different. This shows the dentate gyrus of, which is a region of the hippocampus, which is part of the brain in, in from a mouse, I haven't talked about the mouse yet in any detail but just to show you that you can see patches. It's probably better to see it here in the merge, this is MECP2 and it's in blobs and there are gaps. But actually, there aren't gaps in the nuclei staining and so there are patches of cells here that are inactivated the functional MECP2 gene, and there are other patches here that function that inactivated the non-functional MECP2 gene. And you see these patches, the point I'm making here is the patches in a cat are gigantic and involves millions and millions and millions of cells. The patches in the brain are, for reasons we don't quite understand, tiny and so you get a bigger mixture of functional and nonfunctional cells in this tissue. So, the first thing we did when we found this out was to make a mouse. We were gonna make a mouse anyway for our blue skies reasons but now we were energized, I would say, and that energizing has continued to the present day by the fact that we were working on a human disorder and we're actually in touch with a community of people who are affected by it. So if you take a normal mouse, it lives in this green state for a long time. But the MECP2 minus mouse, the male, the, the equivalent of the human male that doesn't survive, doesn't survive. And these colors are meant to indicate that they get symptoms, get worse and worse, and eventually die. The female and this, this shows a, a sign of neurological symptoms in a mouse. It does this hind limb clasping and it does that at this blue stage here. Initially, there is no observable phenotype. But later on, they become ill and subsequently die. The females and these are really the true model of Rett Syndrome because they're heterozygous as, as geneticists say for these mismutations. They're fine, and that's how you keep the line going. They breed for several months and a mouse at six months of age is quite an old mouse. It's had quite a few liters. But then, they suddenly hit a, a, a wall and they become immobile and they develop all the other sorts of symptoms including hind limb clasping, arrhythmic breathing lack of mobility that, that characterize the Rett-like phenotype. And there's a dramatic change in their behavior but it's stable, just as it is with humans. So if you like though, the MECP2 deficient mouse is actually quite a good model. Not all, not all models are, are particularly persuasive. But it's quite easy to persuade skeptics that this is a good model of this disorder because a lot of the things that MECP2 seems to do in humans it also does in mice. So, we've got, we're armed with this model. Now, how are we going to find out what MECP2 actually does, and how that's connected to the function of the brain? Because that's what's gone wrong in Rett syndrome. Well, the big resource you always have is in, in genetic disorders, is the mutations that give rise to the disorder. Particularly, if, like Rett Syndrome, they're all new mutations. This does not run in families, the males don't survive and the females don't reproduce either. So, it doesn't run in families everything is a new mutation. And so, this is the sort of picture you get. Everywhere, absolutely all over the place. But I will point out to you that these frame shifts, these grey ones, the longest bars, everything downstream of that is disrupted. Because the, the protein goes out of frame when you start making junk afterwards. So, they don't mark the spot where there's an important bit of this protein. They only tell you that this the boundary between and everything downstream gets lost. The other ones, the nonsense mutations, also stop the protein. That's, that's why you put x here. They just terminate the protein. The ones that are most informative are the missed sense mutations. Because what's happened there is, you've put an alien amino acid. One single subunit of the protein in the wrong is wrong. Everything before it, is fine. Everything after it is, fine. Just that one amino acid is wrong. And so this is telling you the really important bits. And if you'll notice, the blue ones, which are the missense are not randomly distributed. So, we went into the database. Now, of course, for a lot of disorders that look like they might be related to MECP2, and there's more than Rett Syndrome. I, I don't have time to go into that. People look at the database. And they start, sorry, they, they sequence. And so, there's an awful lot of polymorphisms, a lot of, lot of changes that are not associated with disease. The one way of being sure it's associated with disease, is to look for mutations that are not found in the parents. They're only found in the offspring. Cuz then, the probability that, that is, is a, is a function-less genetic variant is, is vanishingly low. When you see very specific domains here, interestingly and, I don't have time to go into this, there are now more and more xsomes sequences. People are sequencing genes of normal individuals or for people who have other things. And so, you can find all the missense mutations where there's no obvious effect. And what you notice is that this cluster here, for example, doesn't have any genes with no obviously effect. This cluster here the same. So, you can use the, the normal polymorphisms as a way of seeing the inverse of what you see with the mutations. So, now we have two domains. What's this domain? Well, I've labeled it MBD. Actually, what that stands for is methylated DNA binding domain. I showed you the x-ray structure of that bound to methylated DNA. That's the bit that contacts DNA and brings this in, and many of these mutations prevent that. So, we're pretty clear what's going on, I'm just going to tell you a couple of things about that domain. The first thing that emerged when we studied it was people, you tend to think when you find a DNA binding protein that it goes to specific targets and then, it does stuff there and those targets are its main function. But actually, it turns out, it turns out that MECP2 is incredibly abundant in, specifically in neurons. And in fact, there are 17 million molecules per nucleus in a cell. And this is a lot it's one every four hundred base pairs, it means there's enough to coat the genome and then that's actually what it does. Dna methylation goes up and down along a chromosome so this a very low resolution picture and the MECP2 goes up and down in exactly the same way. So, it's, it's not in special places, it's all over the place, with somewhat different densities and it's very, very abundant. It doesn't behave like a transcription factor which goes to specific target genes, it binds globally. So, that's that domain, let's now talk about this domain and this is more interesting to us. What's more interesting to us, because we had no idea what it might be. So, hypothesis was that this region binds to DNA. And then, this region binds to some sort of partner that it brings in, and that's its job. And you can't mutate that because it fails to do that. And Matt Lyst really led this aspect of the project. What he, we did, was we made a mouse with a green fluorescent protein tag on the MECP2 and then we pull down that tag from the brain, an extract of the brain of the mice that had it. And then, we ask what came down with it, those of the partners? And by mass spectrometry, we found these, these proteins. This is the list of the top 8. Interestingly well, MECP2 came down. That's a relief. You expect, if it didn't, you'd have a real problem. Then two proteins that transport it into the nucleus. But then these 5 subunits and more acronyms, I'm afraid, of a complex that's well-known. This is a huge complex, more than a million daltons complex, which contains which contains a histone deacetylase 3. So, what a histone deacetylases do is, they remove a mark on one of the tails, that mark is associated with activity. If you remove that mark, you work against gene activity. In fact, you silence gene expression. So, this is a complex that reinforces the silence of gene expression. Shuts the genes down by removing this methyl group. So, here it is, there's the methyl group, PowerPoint extravaganza goes. So this, it's well-known to buying nuclear receptors. And it also, now we find that it binds to MECP2. Now, where does it bind to MECP2? Well, it binds it, you won't be surprised to hear, exactly in this second domain. And all of those mutations that cause Rett Syndrome in this second domain, abolish the interaction with this, this complex. So, this mutant protein can't bind DNA. This mutant protein can't bind NCoR SMRT. This what, which is the unfortunate name for this complex. And also, you lose the ability to shut down transcription. So we, we now have this fairly persuasive model I think that MECP2 is a bridge. It's a bridge between DNA, there's a methyl group MECP2 is attached to it. It's brought in this complex which is a gene silencing complex and if you have mutations in the DNA binding domain and it can't bring it in and if you have mutations in the complex interaction, you can't quite bring it in either. So, MECP2 then and other proteins that bind metal CG, and there are others about which we know something. They come in, bind. And instead of creating the sunny atmosphere, they create a foggy trans, transcription-hostile environment. I was going to say like, Edinburgh in January but it's not really transcription-hostile in Edinburgh. We express our genes perfectly well. So then, the big question is, have we got any further now? We know that, it's likely to be a repressor. And to you, it see, it probably seems likely that was always going to be the case. Dna methylation represses transcription, this binds DNA methylation, what more natural than it represses. Actually, it's a very controversial area, as to whether or not it does repress transcription. And my feel is, is, is that the important advance. So the question is what transcription does it repress because it's not obvious. When you look in the brains of the mice, histone acetylation is up, histone H1 is up. The epigenome is disorganized, expression of some genes is up, other genes is down, other genes are down. Or and some are unchanged and these effects aren't very big. So, very, very briefly, I'm going to say you could be controlling the activity of specific genes, you could be controlling transcription in response to neuronal activity only when neurons fire, something happens, this protein actually gets phosphate groups added to it, maybe that's something to do with it or dampening of transcriptional noise. And this is a, a boring sounding possibility, it just kind of sits on the genome and keeps everything down. But there's some evidence for that, we know that the transposons, which are selfish elements in the genome that like to jump around when there is, normally, they jump around, represented by these yellow dots, a very small amount. When you don't have MECP2, they jump around an awful lot more and so, in other words, MECP2 is preventing the expression of the RNA that allows these things to move, and this is no function for the organism. It's actually something it would prefer to keep quiet. So, that's noise dampening, so this question is unresolved. So now, in the last part of my talk, I, I, I left you there with, that's as far as we got with the Molecular Biology I'm afraid. But I think we're now making progress. Now, we know we have this bridge model. Let's now talk about the pathology and the trying to get all the way from the Molecular Biology up to the patients, and our, surrogate for the patients which is the mouse model. So what we really want to do is have a molecular description of the legion in MECP2 and the count for all steps to, the brain of the patient, so that we can understand. And this requires we know an awful lot more than we do now, for example, how brains work. So we're trying to bridge this gap. Now our involvement in this is really to do with one specific question and that is this one. Can the symptoms be reversed? In the pathology, as observed in post mortem brains and as seen in the mouse, is that neurons are slightly simpler. So, if you put a, a bulls-eye over the center of a neuron then its arms are more complex and branchy in a normal animal compared to what they are in an animal that doesn't have MECP2. That's about it for pathology. There's no cell death so it's not a neurodegenerative disorder. It's not like Parkinson's or Alzheimer's or Huntington's, where nerve cells die. It's just a kind of shrinkage they become underpowered neurons. So, the question then arises, if their not dead, if we put MECP2 back, can it be reversed? And I'm gonna tell you about that and then our attempts to do some therapy based on that. So how do you, how do you have the, how do you do this experiment? Well, what you do, is you take the MECP2 gene, you put a stop in it, which is just a chunk of DNA that is poisonous for transcription and then you flank it with sequences that mean, that when you want to you, and so that then causes transcription to stop. You're let the animal grow up, it has no MECP2 and it becomes ill as a result and then, at your chosen moment, you remove that stop and start transcription again and you can do that in ways that I, that have been published and I can tell you about if, if you want to know afterwards but this works and that's the first surprise that actually works. And the reason why it works is because Jacky Guy, who's an unbelievably talented person in the lab is took charge of these experiments. So, I've shown you the mouse that's wildtype, the mouse that's male. What we're going to do now, is look at a mouse where it's male, it's on the, it's in the death zone, if you like. It's and we interject it with tamoxifen, which is the way we trigger the deletion of the stop cassette. Does it work? Well, this is the, this is MECP2 in a normal mouse brain. This is in a stop mouse brain. So, the stop works. This, this looks like it's cell that haven't been stopped. But actually, it's blood cells that autofluoresce . And then, you treat with tamoxifen and back comes the MECP2. So, that works. And then, he is a mouse on, on the day we started the experiment. So, it is grown up with no MECP2. It have the classic symptoms of the MECP2 null mouse it has this tremor, it has arrhythmic breathing which you may be able to see in the flanks. They breathe and then it stops. They breathes and stops. And it doesn't move. And the film is much longer than this and it still doesn't move. And then when you humanely suspend it by the tail, it, it does this hind limb clasping. So, then, then the question is what does tamoxifen do for that? And then, this is the same mouse a month later. Under our animal license, this mouse would not be able to survive for more than a week or two at the most. And here, it is a month later, remarkably healthy. And it went on to live I wouldn't say, a natural life, but you know, a quite a long life. So this is an unexpected finding, we didn't expect it and it turns out nobody else did either. And, and for that reason it was, it, it, it's turned out to be quite important in the field there. This somewhat unedifying image of a mouse I will leave you and go, go on to the, the females. Because, you know, those mice are young. They're only 6 or 8 weeks old, and so, it could be that they're young and plastic, and, and reversal therefore, works better at that age. Also, they're not real model of Rett Syndrome. This is the real model of Rett Syndrome, and these animals are no longer young and plastic. So, we want to do this experiment. Inject with tamoxifen when the animals are 6 months old or so. And then this just shows that this also works. That's a reversed animal, that's a, a wild type animal, a normal animal and you can see they're indistinguishable. And this is an animal that was unable to respond to tamoxifen for the, for the, because we genetically made it that way. So, it's still is obese, which is a characteristic of the females on this genetic background. Immobile, and it does the hind limb clasping and breathing arrhythmia and all that sort of stuff. So, you can this, this mouse looked like that mouse when the treatment started. So, the implications of this reversibility is that, obviously, Rett Syndrome is potentially a curable condition. You have to use the potentially word there because these are mice, not humans. But nevertheless, it's encouraging. It also means, Rett Syndrome, like most of the autism diseases, have been called neurodevelopmental disorders. And the implication is that something goes wrong during development in terms and that you can never recover from that. And, and I, I think that when one thinks of brain diseases, brain disorders one tends to think of them as irrevocable. And in, in actually, there's no, the experimental evidence to support that is, is not strong. And this questions that, and there's work with fragile X Syndrome as well, and other so-called neurodevelopment diseases disorders that suggest that actually they're not neurodevelopmental at all. And, in fact, if you take away MECP2 in adults, adults die. Certainly, not only required during development, and so this reversibility may be more widespread and true than was previously thought, and that can only be good in terms of exploring therapeutic options. Everything we've done suggests that actually what MECP2 does is sustain neuronal function. These are cells that are never going to divide. They take ages deciding who they're going to be connected to. And in an elaborate dance of synaptogenesis and culling of excess neurons and then they never get to refresh themselves and so maintenance is probably a vitally important function and I think MECP2 may be one of the proteins that does that. So, that's just a hypothesis at this point. So, prospects for therapy, you could do all sorts of things. And for time reasons, I'm not going to go through this. I'm just going to talk about our attempts to do gene therapy. The dose of this protein is critical. So, gene therapy doesn't sound very promising. But I'm just going to show you some results. Because I think gene therapy or more likely, gene editing, is the logical end point of the genomics revolution. Having found all these genetic variability associated with disease what better than to be able to fix it. And I feel that where, this is what's going to take awhile of basically engineering to find out exactly how we should do that. So, this by comparison with that aspiration, is very primitive. This is a Adeno-associated virus. And the experiments here were done in collaboration with Gail Mandel of Howard Hughes Medical Institute in Oregon and her laboratory and[UNKNOWN] Helene Cheval did the experiments as well. So we take this, this MECP2 promoter. We drive a, a truncated MECP2 gene, not much fits into these viruses, and they don't replicate. You then, in put them in and there are 2 ways. And you can go directly into the brain through 6 bore holes in the brain which is very laborious. And this doesn't actually work very well. But what Gail Mandel's lab did was to use this virus in an unexpected way, namely, to put it in the systemic circulation system. So, put it in through the facial vein or through the tail vein and then, in females that are 7 to 12 months old. So, this is the real rats model and ask what happens and their, their improvements are quite dramatic. This is rotter rod, it's a wheel you put a mouse on, turn it round slowly and they fall off. But it takes them a while to fall off. And actually, the first day they fall off more quickly than the second day when they've learned a bit, and then the third day, they're a bit better. The animals, without MECP2 we've stopped MECP2 acquired sorry, without MECP2 acquired bad at this. But then, if you put in this virus, you're getting a significant improvement. This is the so-called inverted grid test, which is simply taking the lid off the cage, and turning it upside down. So, that's rather a fancy name for that. And you see how long before they fall off. And you see that the red the red bar is the way they are when you without MECP2. And these, these are the rescued mice, they've improved a lot. And the third test, and there are other tests I could show you, is the nesting test. You weigh a certain amount of nesting materials, you plonk it in the cage and then the next day you come back and see how much of it they've used to make a nest. So it gives you a number. And the not much of it is gone with the mutant mice. A lot is gone with the normal mice, and the rescued mice are vastly better. So I'll finish up by showing you as the final thing, a couple of mice. This is not as good as an experiment that I showed you before. There, I showed you one mouse before and after. This is, for obvious reasons a mouse that's had the virus, treated with an empty virus so it has the virus but it didn't have anything in it. And this is the, this is the way, it, the symptoms looked in a females, that almost you can imagine the high, the, the, the, the limb clasping very immobile and clearly not that healthy. And then, this is an example of a mouse that whirls like that. But now as, as a result, it's a different mouse as a result of receiving the virus, it's vastly improved. This is the data of Saurabh Garg in the Mandel Laboratory with whom we are collaborating. So this, I would hesitate to say that this is a therapy that necessarily can be adapted to humans rapidly because the viral load would be colossal. The amount that gets into the brain is relatively small and 10% of humans have antibodies against these viruses anyway. But it's a basis. So, research into the causes of Rett Syndrome is currently a hot area in biomedical science. Epigenetics, yes, the epigenomes disturbed in these mice and brain autism, these are fascinating areas that are combined in this in this field. Findings over the past decades, actually changed our perception of this disorder and by implication of others. And by that, I mean, reversibility, because it was thought to be impossible. The search for potential therapies is going on a pace. I showed you what we're doing. We are far from a learn, there's lots going on, and no approach is yet proven to work clinically. There is a way to go yet, unfortunately, it's frustrating that one feels one is quite close if only one could engineer something that would do it. And the goal remains to discover robust treatments that either reduce or even eliminate the burden of Rett Syndrome. So, just to summarize then the whole thing, we've ranged over quite a lot. Epigenetics is more or less how the genome of living things is organized and managed. It's a high level word. There's no worry about exactly what it means. Every definition is, encompasses fascinating biology. Cg is a genome signaling module, module. It's very short, it sounds too short to be useful but I hope you're persuaded that actually it is used as a way of, say, adapting regions, adapting regions of the genome to their function. Proteins that read different chemical forms of CG, unmethylated, methylated, lead to contrasting biological outcomes. And mismanaged, disorganized epigenomes are involved in disease. And the extent to which they are involved in disease, is actually profoundly unknown. And, for that reason, epigenome manipulation, for example, pharmacologically, may have therapeutic value in diversed human disorders. Epigenetic drugs, so-called, are already in the clinic, the histone deacetylase is its inhibitors, etc. And there are far more in the pipeline. I would say that we don't really know what they're gonna be good for. Because there could be all sorts of disorders where global epigenome mech, manipulation has a consequence. And so, I think we're in for exciting times. This is my lab. I, this is not my whole lab. This is just, it's people who were in my lab, whose data I've shown. People who are in my lab, whose, some of whose data I've shown. Gail Mandel, who I'm grateful to for allowing me to use our the, her data the data that was generated in her lab on the gene therapy. Brian Kaspar, who made the viruses for her and, and us. And Stuart Cobb and colleagues from Glasgow University who are our nearest, tell us about neuroscience of which we're ignorant. And finally, all this plethora of funding agencies from the very small to the very large who have made our work possible over the years. And this is my lab. I wanted to go to north of Scotland for our retreat. They wanted to go somewhere hot and they won. So, this is Barcelona again. Thank you very much. >> Thank you, Adrian for a splendid lecture, and, and Adrian will now take questions for ten minutes or so. There's one over there. If you if you have a question, if you'd like to ask one, put your hand up in advance, there are two roving mics so we can send one near you so that we can keep the questions coming. >> Hi there you recently published an article in The New Scientist, about epigenetics I wonder if you've got time just to mention a little bit about the post mortem suicide data that you came across. You weren't able to talk about it at length in your article, but I wondered if you could briefly mention a point about that? >> It's not my data, it's, it's a report that people who had committed suicide claiming to have been abused as children were, had a different degree of methylation of a stress hormone receptor promoter in their brains. And I don't feel, and I'm not sure the authors would feel despite their elevated status of the publication, that they have achieved statistical significance with just 12 and also leaving out, as it says in the method section, outliers, that presumably didn't fall within their average. So, I feel if you know, the way you treat your children becomes hardwired in, into their lives at, through this epigenomic mechanism I feel before one announces that to the world, one has to be pretty sure. And I don't feel, in this case, they could be. >> At the back. >> If there's a guard, guardian of the genome, is there a guardian of the epigenome? >> Sorry, I missed the very first phrase. >> If there's a guardian of a genome, is there a guardian of the epigenome? >> A guard, is there a guardian of the epigenome, I don't know, this is a phrase and people, I mean, guardians of the genome are proteins like P53 that takes steps when the genome is damaged. It's not really clear if damaging the epigenome. The epigenome is quite in a state of flux. There is no one epigenome. Now, that's really the problem with epigenome analysis, epigenomic analysis. Every cell type will have a different one and actually, do , so it depends on your stance, some people believe that the epigenome is somewhat fixed and the genes operate within this rather inflexible set of rules. I, from what I have seen, find the epigenome does what its told by the genes and their transcription factors. In a way, the epigenome adapts the genome to its function as determined by other proteins. Now, that's, there's a question of degree between those 2 extremes. But I don't see the epigenome as something that gets fixed, and then is transmitted forever, and you can't do anything about it and even your grandchildren can't do anything about it, two generations later. That, there may be some of that going on. But I feel it's likely to be far less than is sometimes suggested. It's dried up the questions. >> Another one, 4 rows from the back. Oh, there's one here. Okay. Speaker:[cough] Why does it take so long for clinical symptoms to become manifest, both in the mice and in the humans? >> Let, that's a very good question. We actually haven't the faintest idea, I mean, you could argue so in the case of humans, the time when they get it, 18 months of age is a time of great activity in the brain. And so, you, that sort of fuels the idea that this is a neurodevelopmental disorder and you only really start getting the problems when the brain is going through particular types of dance of the neurons in particular synaptogenesis . But actually, in the, in the mouse, if one looks at that, these mice are 6 months old, they're, they're not going through any developmental processes at all as far as we know, they're, they're just gradually aging like, like the rest of us. So in that case, it doesn't quite fit. And I think that the alternative hypothesis is, that without MECP2, the functional half life of your neurons, not their lives but their functional half life is reduced. And they, you, you've crossed some threshold at which the brain stops to, stops working properly. But actually, I don't have a satisfactory answer for your question. So, it's, it's one of the key questions. >> Hi, my questions is about gene therapy and one of the limitations of this is that you can't cause large enough change throughout the entire tissue to correct the fault. And I was wondering whether or not you thought that gene therapy had greater therapeutic impications for epigenetic disease rather than genetic disease. >> Well, I'm not quite sure about the link between the first bit of your, I mean, I agree with the, the, the reservation that you have to hit a high, a high percentage of cells. Actually, these adeno-associated viruses do that. They've selected stereotypes. They're all naturally occurring, none of them have been engineered in any way and so there's scope to improve them. But they spread throughout the brain so the systematic injection if you look in the brain, it's everywhere. So, it, it does get everywhere and if you do the injection into the brain, and these are, there are clinical trials now for[UNKNOWN] disease, lysosomal storage disease where there are 6 bore holes and they're putting it in and they're getting a big spread through the brain of the, this virus. They don't, they don't divide, and they keep churning out the protein for a very long time. So, I think that sort of thing can be solved. I wouldn't say that gene therapy, I mean, gene therapy, this is a blunder buster approach. You've got, you're shoving in an uncontrolled number of genomes into cells different numbers into different cells. It's, it's the primitive end of what hopefully ultimately will be a rather sophisticated therapy. But I wouldn't say it's for epigenetic, rather than genetic. I haven't seen anything that suggests to me that it prefers one or the other. >> Well, I, I was also going to ask, whether or not it was the case of being the opposite when you said that the, the epigenome was constantly in flux. So, does that mean using gene therapy to try and to correct the epigenome is actually more difficult than gene therapy? >> What you've got to remember is that Rett Syndrome is a genetic disorder. It's, it's it affects the epigenome. There, there aren't epigenetic disorders and genetic disorders necessarily. This, the, the, the, the mutation is a standard mutation in a gene, and it's inherited in a Mandelian manner if you, you know, in those very rare families where it's transmitted. So it's a genetic disorder that effects the epigenome. It's not an epigenetic or genetic disorder. >> So, so, Adrian, do, do the virus treated mice, do they stay cured? >> Well. >> Or do they get well again when they get older? >> That's a good question and we don't know because actually those pictures were only taken within the last 4 weeks. They've lived for four weeks beyond that. >> One at the very back. >> But actually, the model experiments say that these things are expressed for a very long time. They don't ever get integrated, and for that reason, it seems they don't seem so susceptible to being shut down by the epigenetic mechanisms that are scouting for strange things in the genome. >> Hello. What's your feeling about the big psychiatric disorders like schizophrenia and bipolar affective disorder and so on? Do you think your research in these epigenomatic processes, approaches are going to be important for those? >> I don't know, there's a, you know people argue about autism. As to whether or not it's more environmental than genetic. And there's now really quite strong evidence that it's genetic. But it's not one genetic disorder. It's hundreds of genetic disorders, actually, literally. There are very many genes that are contributing to autism. That's why it's been so difficult to pin down genetically. So, I would say autism, this work is related to you know, relevant to, it's difficult to know psychiatric disorders. You know, they tend to, autism, despite being caused by large numbers of different genes, where almost no two patients have the same set of genetic lesions, nevertheless have common presentations, features that are in common among them. So, it's almost as though when there are problems with the brain, it gravitates towards certain types of behavior. So, either it doesn't work at all, in which case, survival is, is in question or it gravitates toward certain types of presentation. So, in other words, it says more about the way in which the brain can cope than about the function of the proteins. Now, I, I would say schizophrenia is a very interesting question. They're having meetings about schizophrenia and bipolar, always been groups that go off and talk about the possibility that's it's pure, called what's purely by epigenetics and the environment. But I think, increasingly, as more and more sequencing gets done, my bias would be that they will find, we will find genetic causes for these disorders, and then all of the[UNKNOWN] of ways of dealing with genetic disorders will be drawn upon to try and fix that. To me, one surprising thing of that, if I may,[UNKNOWN], the brain, you would have thought, is the most inaccessible place to ever do stuff like gene therapy. But actually, it's quite a good place because the cells don't divide, there's not there is immune response in there but it's nowhere near as virulent as it is in other places, so you can do more stuff in the brain and things will spread through the brain, so maybe that will apply to the disorders you are talking about, but it's really a long way away, I think. >> Is anyone working on Friedreich's ataxia? >> Friedreich's ataxia? >> Yes. That's where they. >> Lots of people are working on, on Friedreich's ataxia but you're not talking to the right person to ask about it unfortunately. I mean, I, I, I would need a quick reminder about exactly what the lesion is, is it DNA repair? I can't remember, can anyone remember? Dna repair, yes, that would be very different if it's, if the lesions due to DNA damage then, then that's not really quite in the league of epigenetics as we've been discussing it. But rest assured, Friedreich's ataxia is a very active area of research. >> Okay. There's one there. Then, one in the green cardigan and then, one against the wall and we might have to wrap it up that, that point. >> Yeah. Fantastic talk, Adrian. It's interesting that you observed obesity in the, the mice. Were any aspects of feeding or weights changed with the adeno virus treatment? >> Well, unfortunately, we've never really investigated that. I think they don't eat more, I think it's probably but, but we don't really know. All I can tell you when you do the reversal, it's the nicest thing to watch, you just simply watch them come down over a period of three weeks, their weight goes from being obese to being normal. So, but on the other hand, we're, we're activating MECP2 in every cell in the body. And that actually is an area we're interested in now because are there also peripheral, neuroscientists call everything that isn't the brain, the periphery, for some reason but are there peripheral phenotypes that we've been missing, perhaps. >> Okay, I hope these are two quick questions. >> Hello, I was just, just to ask about that. So you, can you see more[UNKNOWN] cells in other organisms, or organs, and does they have >> We've never looked. >> And some genotype. And, and, another more thing, so if it's not like that, it means that in some cases, some cells will be dying because they don't express it, and so they are kind of selected and because in the brain they cannot. >> No, but that's, that doesn't happen, you see. >> Okay. >> You, you, you can, the cells without it don't die. That's why reversal is such an interesting possibility, and in fact, with respect to[UNKNOWN] and other tissues, there are so, there's quite a variation in the severity of Rett Syndrome. And quite often, it's due to skewed x chromosome inactivation in the population. There's quite a variation, it isn't always 50-50, half of the paternal, half of the maternal. Quite often, it's very skewed, like one in 10, one in 20 one in one and two in 10, it's very skewed. When the skewing is against the mutated version, the symptoms are much milder and so you get what's called a speech preserved version where, you know, there, there is a spectrum to normality. Now, you did measure that by looking at the blood. So, presume, whatever you find in the blood looks as though, quite often, it reflects what's going on in the brain. >> Okay, thanks. Is there one last one? >> Thank you. Do all animals have epigenomes? Or is it just a characteristic of the higher animals? >> Even, even yeast has marks on its genome. Actually, yeast doesn't have DNA methylation. C elegans, this worm, doesn't have DNA methylation. Drosophila melanogaster has virtually no DNA methylation. So, the models that are quite often worked on, don't. That's chosen actually quite often because they're, they have a small genome rapid generation time. But those animals, nevertheless, have what one would call an epigenome, because they have histone tails covered in marks. So, these are quite conserved to, throughout all, all organisms that one would call eukaryotes. That's animals, plants, fungi. >> Okay on that affinitive note, the I think we could have kept on going for much longer with the questions but Adrian has another rest of his program to get through, so I was asked to bring this to a halt the floor, the floor now actually. I think you've done rather well out of it. As expected, Adrian has given us a wonderful lecture, wide ranging, quite challenging and he has covered a, a very large area so thank you very much for that. And now, I want, going to ask Patrick Vallance, who is the President for Pharmaceutical R&D at GSK to come and present Adrian with his medal. Patrick joined GSK as Head of Drug Discovery, I think in 2000? 2000 and 2006. And he's now President of R&D Pharmaceuticals. What's that? Oh, yes he's the man with the monies. He's the one actually giving the check. >> Yeah, I'm the man with the check. And you're giving the medal. Adrian, thank you very much, it was absolutely terrific, and it's a real privilege, for GSK to be able to fund this lecture and prize. And it's been a privilege for GSK, or its precursor companies, for 32 years, as Jean said, that we started with the Wellcome Foundation in 1980, and then, GlaxoWellcome, and now, GSK. And some things have stayed constant over those times and some things have changed. The company is much, much bigger. The company is totally global. And, of course, the whole nature of drug discovery and development has changed. But some things have stayed constant. And one of the things that stayed constant is our base in the UK and our commitment to the UK and just about 50% of our R&D activity is in the UK. And one of the reasons that we're here is excellence of the science base and I think that's been admirably demonstrated today, Adrian, by what you've said and, of course, is embedded in the values in of this institution. The second thing that stay constant, perhaps not constant, but in a way, started at the beginning, and is very, very important to us now, is a very close working relationship with academics. I think it was absolutely the hallmark of the Wellcome Foundation. And I think it's absolutely the hallmark of what we're doing now. And it's perhaps no surprise, that I think it was 5 or 6 years ago when we decided that we needed to understand what the opportunities were in epigenetics for drug discovery. We reached out to the very leading academics in this field to find out what we should be thinking about. And Adrian, it was you that came in to talk to some of our team to help us to get started on that. So, it's terrific to hear this today. Unbelievably impressive and Jean gives the lasting thing, which is the medal and I give the transient thing, which is the money. But I hope it brings some pleasure and thank you very much indeed. >> Thank you very much. Thank you very much, thank you.
B1 gene dna genome epigenome epigenetics protein Genetics, epigenetics and disease 265 23 Kelvin posted on 2015/11/16 More Share Save Report Video vocabulary